BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34648367)

  • 1. Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic.
    Kaufman HW; Chen Z; Niles JK; Radcliff J; Fesko Y
    JCO Clin Cancer Inform; 2021 Sep; 5():1028-1033. PubMed ID: 34648367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Prostate Cancer Screening in the Pre- and Peri-COVID-19 Pandemic Period.
    Davis M; Stephens A; Butaney M; Morrison C; Corsi N; Sood A; Levin AM; Cole A; Trinh QD; Rogers C; Abdollah F
    Urol Pract; 2023 Nov; 10(6):631-637. PubMed ID: 37647197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts.
    Epstein MM; Sundaresan D; Fair M; Fouayzi H; Warner ET; Garber LD; Gurwitz JH; Field TS
    Cancer Causes Control; 2022 Oct; 33(10):1313-1323. PubMed ID: 35933572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans.
    Klaassen Z; Stock S; Waller J; De Hoedt A; Freedland SJ
    JAMA Oncol; 2022 Jun; 8(6):914-918. PubMed ID: 35389461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of COVID-19 on prostate cancer testing in Australia.
    Jain A; Macneil J; Kim L; Patel MI
    BMC Urol; 2022 Jun; 22(1):88. PubMed ID: 35729543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.
    Lavallée LT; Binette A; Witiuk K; Cnossen S; Mallick R; Fergusson DA; Momoli F; Morash C; Cagiannos I; Breau RH
    Mayo Clin Proc; 2016 Jan; 91(1):17-22. PubMed ID: 26688045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Ng Hung Shin B; Tan S; Rhee H; Chung E
    Int J Cancer; 2024 Mar; 154(6):1003-1010. PubMed ID: 37921494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
    Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
    Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
    Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
    BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
    Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
    Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.